Change in Serum Hepatitis B Surface Antigen Level and Its Clinical Significance in Treatment-naïve, Hepatitis B e Antigen-positive Patients Receiving Entecavir

• DOI: 10.1097/mcg.0b013e3181d52946
• Publication Date: 2010-03-26T09:37:43Z
• Authors: Young Kul Jung; Ji Hoon Kim; Young Sun Lee; Hyun Jung Lee; Eileen Yoon; Eun Suk Jung; Seung Kwon Hong; Moon Kyung Joo; Jong Eun Yeon; Jong Jae Park; Jae Seon Kim; Young-Tae Bak; Kwan Soo Byun
• Keywords: Entecavir; HBeAg; Hepatitis B

We investigated changes in hepatitis B surface antigen (HBsAg) level and its correlation with clinical outcomes treatment-naive chronic (CHB) patients undergoing entecavir therapy.Among 51 e (HBeAg)-positive CHB receiving for more than 1 year, 28 were enrolled. HBsAg levels measured at baseline, 6 months, 12 months after treatment using the Architect QT assay (Abbott, dynamic; range: 0.05 to 125,000 IU/mL). Serum alanine aminotransferase, HBeAg, anti-HBe, virus (HBV) DNA (Cobas Taqman: low detection limit 1.84 log10 copies/mL) baseline every 3 months. The response was defined as an that decreased IU/mL from treatment.Twenty-eight treated a median period of 21 (range: 18 24 mo). showed mean 4.0, 3.7, 3.6 pretreatment, 6, respectively, declined significantly (P<0.001). HBV 8.1, 3.1, 2.4 copies/mL decline correlated (γ=0.391, P=0.044). Five response, cumulative incidence HBeAg loss year 80% versus 30% those without, respectively (P=0.034).Monitoring quantitative could be useful parameter assessing therapy HBeAg-positive patients.